Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry-Reference-Cited by-同舟云学术

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry

Published:2020-11 Issue:11 Volume:17 Page:1413-1423
ISSN:2329-6933
Container-title:Annals of the American Thoracic Society
language:en
Short-container-title:Annals ATS

Author:

Salisbury Margaret L.¹^ORCID,Conoscenti Craig S.²,Culver Daniel A.³,Yow Eric⁴,Neely Megan L.⁴⁵,Bender Shaun²,Hartmann Nadine⁶,Palmer Scott M.⁴⁵,Leonard Thomas B.²,Baker Albert,Beegle Scott,Belperio John,Condos Rany,Cordova Francis,Culver Daniel A.,Dilling Daniel,Fitzgerald John,Flaherty Kevin R.,Gibson Kevin,Gulati Mridu,Guntupalli Kalpalatha,Gupta Nishant,Case Amy Hajari,Hotchkin David,Huie Tristan,Kaner Robert,Kim Hyun,Lancaster Lisa,Lasky Joseph A.,Lee Doug,Liesching Timothy,Lipchik Randolph,Lobo Jason,Luckhardt (formerly Joao de Andrade) Tracy,Mageto Yolanda,Malik Numaan,Menon Prema,Morrison Lake,Namen Andrew,Oldham Justin,Paul Tessy,Podolanczuk Anna,Porteous Mary,Raj Rishi,Ramaswamy Murali,Russell Tonya,Sachs Paul,Safdar Zeenat,Shafazand Shirin,Siddiqi Ather,Sigal Barry,Strek Mary,Suliman Sally,Tabak Jeremy,Walia Rajat,Whelan Timothy

Affiliation:

1. Vanderbilt University Medical Center, Nashville, Tennessee

2. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut

3. Cleveland Clinic, Cleveland, Ohio

4. Duke University Medical Center, Durham, North Carolina

5. Duke Clinical Research Institute, Durham, North Carolina; and

6. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

Publisher

American Thoracic Society

Subject

Pulmonary and Respiratory Medicine

Reference37 articles.